Dr. David Lebwohl, scientific advisor to Avotres, is the Chief Medical Officer of Intellia Therapeutics which creates novel engineered cell therapies for immuno-oncology and autoimmune diseases with CRISPR/Cas9-based genome editing technology. He was the former Chief Medical Officer of Semma Therapeutics, a subsidiary of Vertex Pharmaceuticals, focusing on curing type 1 diabetes with stem cell technology.

 

Dr. Lebwohl was previously at Novartis Pharmaceuticals, where he served as Senior Vice President and Franchise Global Program Head of the CAR T team. Dr. Lebwohl has led the development of Kymriah, resulting in the approval of the first BLA for a CAR T worldwide and the first approval of a CAR T for two indications. Before that, he served as Global Head of Oncology Clinical Development and Global Program Head for Afinitor, an oral mTOR inhibitor, within Novartis, where he was responsible for its development from phase 1 through five NDA/MAA approvals in five indications.  

 

Prior to joining Novartis in 2002, Dr. Lebwohl served as a Group Director of Clinical Oncology at Bristol Myers Squibb. Following post-graduate training at Brigham and Women’s Hospital and Memorial Sloan-Kettering Cancer Center in internal medicine, hematology and medical oncology, he joined the staff at Memorial Sloan-Kettering as a Clinical Assistant Physician.  

 

Dr. Lebwohl received a Doctor of Medicine degree from the Yale University School of Medicine and has an undergraduate degree in Biochemical Sciences from Harvard College.